WAM
NRSNW icon

Warberg Asset Management’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History

Warberg Asset Management’s Portfolio NRSNW Stock Details NRSNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,000
Closed -$2.05K – 204
2025
Q1 		$2.05K Sell
10,000
-7,936
-44% -$2.08K ﹤0.01% 179
2024
Q4 		$7.89K Sell
17,936
-2,265
-11% -$606 ﹤0.01% 167
2024
Q3 		$3.43K Sell
20,201
-11,805
-37% -$2.01K ﹤0.01% 185
2024
Q2 		$6.59K Sell
32,006
-9,400
-23% -$2.16K ﹤0.01% 185
2024
Q1 		$17.4K Sell
41,406
-22,096
-35% -$5.56K ﹤0.01% 156
2023
Q4 		$4.96K Sell
63,502
-12,607
-17% -$1.75K ﹤0.01% 191
2023
Q3 		$11K Sell
76,109
-1,600
-2% -$291 ﹤0.01% 170
2023
Q2 		$15.4K Sell
77,709
-56
-0.1% -$18 ﹤0.01% 168
2023
Q1 		$30.3K Sell
77,765
-1,903
-2% -$606 0.01% 158
2022
Q4 		$14.4K Sell
79,668
-2,232
-3% -$563 ﹤0.01% 191
2022
Q3 		$19K Buy
81,900
+4,800
+6% +$1.24K ﹤0.01% 205
2022
Q2 		$39K Buy
77,100
+53,104
+221% +$21.9K 0.01% 159
2022
Q1 		$14K Sell
23,996
-42,610
-64% -$27K ﹤0.01% 195
2021
Q4 		$61K Buy
+66,606
New +$59.3K 0.01% 147

Other funds holding NRSNW

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Warberg Asset Management's NRSNW Position: Q2 2025 in Review

Warberg Asset Management sold out of NeuroSense Therapeutics Warrant (NRSNW) in Q2 2025, closing a stake of 10,000 shares — an estimated $2.05K sold.

Warberg Asset Management first reported a position in NRSNW in Q4 2021 and held it in 14 quarters. The position peaked at $61K in Q4 2021. 2 funds tracked by Wall St. Rank hold NRSNW as of Q2 2025.

  • Warberg Asset Management reported no remaining NeuroSense Therapeutics Warrant position as of Q2 2025 after selling out during the quarter.
  • Warberg Asset Management sold 10,000 NeuroSense Therapeutics Warrant shares in Q2 2025, an estimated $2.05K.
  • Warberg Asset Management first reported a position in NeuroSense Therapeutics Warrant in Q4 2021 and held it in 14 quarters.
  • Warberg Asset Management's NeuroSense Therapeutics Warrant position peaked at $61K in Q4 2021.
  • 2 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q2 2025.

Based on Warberg Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.